A Price Too High: Cost, Supply, and Security Threats to Affordable Prescription Drugs

Thumbnail Image
Serial Number
Levin Center Identifier
Document Date
Report Length
60 pages
Policy Agendas Project Major Code
Additional, Minority, Dissenting Views
Found Using Methodology
Idependent Author(s)
Brief Executive Summary
The Senate Committee on Homeland Security and Governmental Affairs conducted an investigation into the crisis of unaffordable prescription drugs, widespread shortages of prescription and hospital-administered drugs, and over reliance on foreign sources and supplies of drugs sold in the United States. The committee discovered that brand name drug prices continue to increase at record levels, the number and duration of drug shortages continues to rise, and the U.S. dependence on foreign sources of prescription drugs increases security risks.
Press Releases and Contextual Information
Related Hearings
House Committee on Energy and Commerce, Subcommittee on Consumer Protection and Commerce, hearing on "Profits over Consumers: Exposing How Pharmaceutical Companies Game the System," 116th Cong., H.Hrg. 116-63, (2019, September 19)
House Committee on Ways and Means, Subcommittee on Health, hearing on "Promoting Competition to Lower Medicare Drug Prices," 116th Cong., (2019, March 7)
House Committee on Oversight and Government Reform, Subcommittee on Healthcare, District of Columbia, Census and the National Archives, hearing on "Drug Shortage Crisis: Lives are in the Balance," 112th Cong., H.Hrg. 112-102, (2011, November 30)
House Committee Energy and Commerce, Subcommittee on Health, hearing on "Safeguarding Pharmaceutical Supply Chains in a Global Economy," 116th Cong., H.Hrg. 116-76, (2019, October 30)
House Committee on Education and Labor, Subcommittee on Health, Employment, Labor, and Pensions, hearing on "Making healthcare More Affordable: Lowering Drug Prices and Increasing Transparency," 116th Cong., H.Hrg. 116-42, (2019, September 26)
House Committee Energy and Commerce, Subcommittee on Health, hearing on "Examining FDA\342\200\231s Generic Drug and Biosimilar User Fee Programs," 115th Cong., H.Hrg. 115-10, (2017, March 2)
House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations, hearing on "The Heparin Disaster: Chinese Counterfeits and American Failures," 110th Cong., H.Hrg. 110-109, (2008, April 29)
Senate Committee on Armed Services, Subcommittee on Emerging Threats and Capabilities, hearing on "Biological Threats to United States National Security," 116th Cong., S.Hrg. 116-259, (2019, November 20)
Senate Committee on Health, Education, Labor and Pensions, hearing on "Continuing America\342\200\231s Leadership in Medical Innovation for Patients," 114th Cong., S.Hrg. 114-572, (2015, March 10)
Authors–Congress Members
Authors–Staff Members
Authors–Ex Officio Members
Authors–Additional, Minority, Dissenting Views